University of Texas MD Anderson Cancer Center

Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials (2019) Yao J, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, Van Cutsem E, et al. Journal article Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation (2019) Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, et al. Journal article Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia (2019) Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, et al. Journal article Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer (2019) Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, et al. Journal article Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk (2019) Yang Y, Wu L, Shu X, Lu Y, Shu XO, Cai Q, Beeghly-Fadiel A, et al. Journal article Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus (2019) Buckley MA, Woods NT, Tyrer JP, Mendoza-Fandino G, Lawrenson K, Hazelett DJ, Najafabadi HS, et al. Journal article The Immune Landscape of Cancer. (2019) Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Yang THO, Porta-Pardo E, et al. Journal article, Erratum EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. (2019) Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, et al. Journal article Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors (NETs): A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019) Fazio N, Carnaghi C, Valle JW, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al. Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes With Everolimus: A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019) Chan DL, Yao JC, Camaghi C, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al. Conference contribution